Loading...
•
Jul 04
Enovis Q2 2025 Earnings Report
Enovis reported its second quarter 2025 financial results, showing continued commercial momentum with sales growth and updated full-year financial expectations.
Key Takeaways
Enovis reported strong second-quarter 2025 results with net sales of $565 million, a 7% increase year-over-year. The company experienced continued execution in its Prevention & Recovery and Reconstructive segments, stable end markets, and positive momentum from new product introductions. Despite a GAAP net loss of $37 million, adjusted EBITDA reached $97 million, reflecting solid operational performance. The company also updated its full-year 2025 financial outlook, raising revenue and adjusted EBITDA guidance.
Second-quarter net sales increased by 7% on a reported basis and 5% organically compared to the same period in 2024, reaching $565 million.
The Reconstructive segment demonstrated significant growth, with sales increasing 11% on a reported basis and 8% organically year-over-year.
The Prevention & Recovery segment also grew, with sales up 5% on a reported basis and 3% organically from the prior year.
Enovis reported a GAAP net loss of $37 million, but achieved an adjusted EBITDA of $97 million, representing 17.2% of sales.
Enovis
Enovis
Enovis Revenue by Segment
Revenue by Segment
Prevention and Recovery Revenue
CapyFin.comReconstructive Revenue
CapyFin.com Forward Guidance
Enovis updated its financial expectations for the full year 2025, raising its revenue, adjusted EBITDA, and adjusted earnings per share guidance, reflecting confidence in continued growth.
Positive Outlook
- Full-year revenue guidance increased to a range of $2.245 billion to $2.275 billion, up from prior expectations of $2.220 billion to $2.250 billion.
- Adjusted EBITDA forecast raised to $392 million to $402 million, compared to the previous outlook of $385 million to $395 million.
- Full-year adjusted earnings per diluted share guidance updated to $3.05 to $3.20, an increase from the prior range of $2.95 to $3.10.
- The updated guidance reflects continued commercial momentum and strong performance in key segments.
- Management expresses confidence in driving durable, profitable growth and unlocking the full value of their orthopedic platform.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The company did not provide a GAAP net income or EPS guidance for the full year, making it difficult to assess the GAAP profitability outlook.
- Potential risks mentioned include impacts of public health emergencies, global economic disruptions, and macroeconomic conditions like inflation.
- Changes in government trade policies and supply chain disruptions could affect future performance.
- Increasing energy costs and availability concerns, particularly in the European market, are noted as potential challenges.
Revenue & Expenses
Visualization of income flow from segment revenue to net income